|View printer-friendly version|
|Date:||Wednesday, June 5|
A live webcast of the presentation can be access using the following link: http://www.veracast.com/webcasts/bio/internationalconvention2019/81201224287.cfm
A replay of the webcast will be available through
The Convention allows for public and private companies to provide company presentations, request meetings with biotech investors and executives, attend educational sessions and engage in networking opportunities.
For more information, please visit: http://convention.bio.org/about-bio-convention/.
DetermaVu™ is being developed as an intermediate step to confirm the absence of cancer between imaging modalities (LDCTs) detecting suspicious lung nodules and downstream invasive procedures that determine if the nodules are malignant.
DetermaVu™ has the potential to dramatically reduce U.S. healthcare costs by billions of dollars each year by eliminating unnecessary biopsies, which, according to a study of
DetermaVu™ is a trademark of
LifeSci Advisors, LLC
LifeSci Public Relations